Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of amoxetine hydrochloride enteric-coated tablets for major depressive disorder
CTR20244865Phase 3Active
- Sponsor
- Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atomoxetine in major depressive disorder (MDD) (3 arms), sponsored by Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences. Primary endpoint: Change from baseline in MADRS total score at week 8. Started Feb 2025; status: active.
02
Drugs
atomoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20244865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244865.